Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Tdap Vaccine

Santos, Jaime; Montellano, May Emmeline B.; Solante, Rontgene; Perreras, Nicole; Meyer, Stéphanie; Toh, Myew–Ling; Zocchetti, Céline; Vigne, Claire; Mascareñas, César

doi:10.1097/inf.0000000000003220

Cited by 1 publication

(1 citation statement)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No safety issues or decreased immunogenicity were associated with coadministration of these vaccines. Trials are ongoing to evaluate concomitant and sequential administration of the Dengvaxia vaccine with a human papillomavirus vaccine among children aged 9-13 years in Malaysia (69) and among children aged 9-14 years in Mexico (70), as well as coadministration with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine among persons aged 9-60 years (71).…”

Section: Administration Of Dengue Vaccine With Other Vaccinesmentioning

confidence: 99%

Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021

Paz–Bailey¹,

Adams²,

Wong³

et al. 2021

MMWR Recomm. Rep.

View full text Add to dashboard Cite

Dengue is a vectorborne infectious disease caused by dengue viruses (DENVs), which are predominantly transmitted by Aedes aegypti and Aedes albopictus mosquitos. Dengue is caused by four closely related viruses (DENV-1-4), and a person can be infected with each serotype for a total of four infections during their lifetime. Areas where dengue is endemic in the United States and its territories and freely associated states include Puerto Rico, American Samoa, the U.S. Virgin Islands, the Federated States of Micronesia, the Republic of Marshall Islands, and the Republic of Palau. This report summarizes the recommendations of the Advisory Committee on Immunization Practices (ACIP) for use of the Dengvaxia vaccine in the United States. The vaccine is a live-attenuated, chimeric tetravalent dengue vaccine built on a yellow fever 17D backbone. Dengvaxia is safe and effective in reducing dengue-related hospitalizations and severe dengue among persons who have had dengue infection in the past. Previous natural infection is important because Dengvaxia is associated with an increased risk for severe dengue in those who experience their first natural infection (i.e., primary infection) after vaccination. Dengvaxia was licensed by the Food and Drug Administration for use among children and adolescents aged 9-16 years (referred to in this report as children). ACIP recommends vaccination with Dengvaxia for children aged 9-16 having evidence of a previous dengue infection and living in areas where dengue is endemic. Evidence of previous dengue infection, such as detection of anti-DENV immunoglobulin G with a highly specific serodiagnostic test, will be required for eligible children before vaccination.

show abstract

Section: Administration Of Dengue Vaccine With Other Vaccinesmentioning

confidence: 99%